BeOne Medicines and partners renew Brukinsa access programme for CLL

BeOne Medicines and The Max Foundation have renewed their partnership to expand access to Brukinsa for chronic lymphocytic leukemia (CLL) patients. Building on a program that has already treated over 300 patients in Armenia, Ethiopia, and Nepal, the renewed agreement aims to reach approximately 1,000 patients cumulatively. Supported by donated drug and a $1m grant, the initiative will continue support in existing countries and potentially expand to others like Côte d’Ivoire and Malawi, ensuring ongoing treatment beyond 2028 if clinically required.